Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

被引:96
作者
Unnikrishnan, Ashwin [1 ,2 ]
Papaemmanuil, Elli [3 ,4 ]
Beck, Dominik [1 ,2 ,5 ,6 ]
Deshpande, Nandan P. [8 ]
Verma, Arjun [1 ,2 ,9 ]
Kumari, Ashu [10 ]
Woll, Petter S. [11 ,12 ]
Richards, Laura A. [10 ]
Knezevic, Kathy [1 ,2 ]
Chandrakanthan, Vashe [1 ,2 ]
Thoms, Julie A. I. [1 ,2 ]
Tursky, Melinda L. [1 ,2 ,10 ,13 ]
Huang, Yizhou [1 ,2 ,5 ,6 ]
Ali, Zara
Olivier, Jake [14 ]
Galbraith, Sally [14 ]
Kulasekararaj, Austin G. [15 ]
Tobiasson, Magnus [11 ]
Karimi, Mohsen [11 ]
Pellagatti, Andrea [16 ]
Wilson, Susan R. [14 ,17 ]
Lindeman, Robert [18 ]
Young, Boris [18 ]
Ramakrishna, Raj [19 ]
Arthur, Christopher [20 ]
Stark, Richard [21 ]
Crispin, Philip [22 ]
Curnow, Jennifer [22 ,23 ,28 ]
Warburton, Pauline [24 ]
Roncolato, Fernando [25 ]
Boultwood, Jacqueline [16 ]
Lynch, Kevin [26 ]
Jacobsen, Sten Eirik W. [11 ,12 ]
Mufti, Ghulam J. [15 ]
Hellstrom-Lindberg, Eva [11 ]
Wilkins, Marc R. [7 ,8 ,27 ]
MacKenzie, Karen L. [10 ]
Wong, Jason W. H. [1 ,2 ]
Campbell, Peter J. [3 ]
Pimanda, John E. [1 ,2 ,18 ]
机构
[1] UNSW, Lowy Canc Res Ctr, Adult Canc Program, Sydney, NSW 2052, Australia
[2] UNSW, Prince Wales Clin Sch, Sydney, NSW 2052, Australia
[3] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Saffron Walden CB10 1SA, Essex, England
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, New York, NY 10065 USA
[5] Univ Technol Sydney, Ctr Hlth Technol, Sydney, NSW 2007, Australia
[6] Univ Technol Sydney, Sch Software, Sydney, NSW 2007, Australia
[7] UNSW, Sch Biotechnol & Biomol Sci, Syst Biol Initiat, Sydney, NSW 2052, Australia
[8] UNSW, School Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia
[9] Univ Technol Sydney, Climate Change Cluster, Sydney, NSW 2007, Australia
[10] Childrens Canc Inst Australia, Sydney, NSW 2052, Australia
[11] Karolinska Univ, Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med,Hosp Huddinge, S-14186 Stockholm, Sweden
[12] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Haematopoiet Stem Cell Biol Lab, Oxford OX3 9DS, England
[13] St Vincents Hosp, St Vincents Ctr Appl Med Res, Blood Stem Cells & Canc Res, Sydney, NSW 2010, Australia
[14] UNSW, Sch Math & Stat, Sydney, NSW 2052, Australia
[15] Kings Coll London Sch Med, Dept Haematol Med, London WC2R 2LS, England
[16] Univ Oxford, Nuffield Div Clin Lab Sci, Radcliffe Dept Med, Oxford OX3 9DU, England
[17] Australian Natl Univ, Math Sci Inst, Canberra, ACT 0200, Australia
[18] Prince Wales Hosp, Haematol Dept, South Eastern Area Lab Serv, Randwick, NSW 2031, Australia
[19] Southern Sydney Haematol, Kogarah, NSW 2217, Australia
[20] Royal North Shore Hosp, St Leonards, NSW 2065, Australia
[21] North Coast Canc Inst, Port Macquarie, NSW 2444, Australia
[22] Canberra Hosp, Canberra, ACT 2605, Australia
[23] Concord Repatriat Gen Hosp, Concord, NSW 2139, Australia
[24] Wollongong Hosp, Wollongong, NSW 2521, Australia
[25] St George Hosp, Kogarah, NSW 2217, Australia
[26] Celgene Int, CH-2017 Boudry, Switzerland
[27] UNSW, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia
[28] Westmead Hosp, Westmead, NSW 2145, Australia
来源
CELL REPORTS | 2017年 / 20卷 / 03期
基金
英国医学研究理事会; 瑞典研究理事会; 英国惠康基金;
关键词
ACUTE MYELOID-LEUKEMIA; CLONAL HEMATOPOIESIS; TET2; MUTATIONS; CANCER CELLS; STEM-CELLS; EXPRESSION; INHIBITORS; IMPACT; AGENTS; TRIAL;
D O I
10.1016/j.celrep.2017.06.067
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only similar to 50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-responders. Here, we show that AZA responders have more hematopoietic progenitor cells (HPCs) in the cell cycle. Non-responder HPC quiescence is mediated by integrin alpha 5 (ITGA5) signaling and their hematopoietic potential improved by combining AZA with an ITGA5 inhibitor. AZA response is associated with the induction of an inflammatory response in HPCs in vivo. By molecular bar coding and tracking individual clones, we found that, although AZA alters the sub-clonal contribution to different lineages, founder clones are not eliminated and continue to drive hematopoiesis even in complete responders.
引用
收藏
页码:572 / 585
页数:14
相关论文
共 44 条
  • [1] Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
    Ades, Lionel
    Sekeres, Mikkael A.
    Wolfromm, Alice
    Teichman, Melissa L.
    Tiu, Ramon V.
    Itzykson, Raphael
    Maciejewski, Jaroslaw P.
    Dreyfus, Francois
    List, Alan F.
    Fenaux, Pierre
    Komrokji, Rami S.
    [J]. LEUKEMIA RESEARCH, 2013, 37 (06) : 609 - 613
  • [2] TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
    Bejar, Rafael
    Lord, Allegra
    Stevenson, Kristen
    Bar-Natan, Michal
    Perez-Ladaga, Albert
    Zaneveld, Jacques
    Wang, Hui
    Caughey, Bennett
    Stojanov, Petar
    Getz, Gad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Chen, Rui
    Stone, Richard M.
    Neuberg, Donna
    Steensma, David P.
    Ebert, Benjamin L.
    [J]. BLOOD, 2014, 124 (17) : 2705 - 2712
  • [3] Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
    Bejar, Rafael
    Stevenson, Kristen E.
    Caughey, Bennett
    Lindsley, R. Coleman
    Mar, Brenton G.
    Stojanov, Petar
    Getz, Gad
    Steensma, David P.
    Ritz, Jerome
    Soiffer, Robert
    Antin, Joseph H.
    Alyea, Edwin
    Armand, Philippe
    Ho, Vincent
    Koreth, John
    Neuberg, Donna
    Cutler, Corey S.
    Ebert, Benjamin L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2691 - +
  • [4] Clinical Effect of Point Mutations in Myelodysplastic Syndromes
    Bejar, Rafael
    Stevenson, Kristen
    Abdel-Wahab, Omar
    Galili, Naomi
    Nilsson, Bjoern
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Raza, Azra
    Levine, Ross L.
    Neuberg, Donna
    Ebert, Benjamin L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2496 - 2506
  • [5] Regulation of DNA repair throughout the cell cycle
    Branzei, Dana
    Foiani, Marco
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2008, 9 (04) : 297 - 308
  • [6] Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
    Busque, Lambert
    Patel, Jay P.
    Figueroa, Maria E.
    Vasanthakumar, Aparna
    Provost, Sylvie
    Hamilou, Zineb
    Mollica, Luigina
    Li, Juan
    Viale, Agnes
    Heguy, Adriana
    Hassimi, Maryam
    Socci, Nicholas
    Bhatt, Parva K.
    Gonen, Mithat
    Mason, Christopher E.
    Melnick, Ari
    Godley, Lucy A.
    Brennan, Cameron W.
    Abdel-Wahab, Omar
    Levine, Ross L.
    [J]. NATURE GENETICS, 2012, 44 (11) : 1179 - 1181
  • [7] The genetic basis of myelodysplasia and its clinical relevance
    Cazzola, Mario
    Della Porta, Matteo G.
    Malcovati, Luca
    [J]. BLOOD, 2013, 122 (25) : 4021 - 4034
  • [8] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Cheson, Bruce D.
    Greenberg, Peter L.
    Bennett, John M.
    Lowenberg, Bob
    Wijermans, Pierre W.
    Nimer, Stephen D.
    Pinto, Antonio
    Beran, Miloslav
    de Witte, Theo M.
    Stone, Richard M.
    Mittelman, Moshe
    Sanz, Guillermo F.
    Gore, Steven D.
    Schiffer, Charles A.
    Kantarjian, Hagop
    [J]. BLOOD, 2006, 108 (02) : 419 - 425
  • [9] Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
    Chiappinelli, Katherine B.
    Strissel, Pamela L.
    Desrichard, Alexis
    Li, Huili
    Henke, Christine
    Akman, Benjamin
    Hein, Alexander
    Rote, Neal S.
    Cope, Leslie M.
    Snyder, Alexandra
    Makarov, Vladimir
    Buhu, Sadna
    Slamon, Dennis J.
    Wolchok, Jedd D.
    Pardoll, Drew M.
    Beckmann, Matthias W.
    Zahnow, Cynthia A.
    Mergoub, Taha
    Chan, Timothy A.
    Baylin, Stephen B.
    Strick, Reiner
    [J]. CELL, 2015, 162 (05) : 974 - 986
  • [10] Activity of Azacitidine in Chronic Myelomonocytic Leukemia
    Costa, Rubens
    Abdulhaq, Haifaa
    Haq, Bushra
    Shadduck, Richard K.
    Latsko, Joan
    Zenati, Mazen
    Atem, Folefac D.
    Rossetti, James M.
    Sahovic, Entezam A.
    Lister, John
    [J]. CANCER, 2011, 117 (12) : 2690 - 2696